Exchange Traded Concepts LLC Sells 43,724 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Exchange Traded Concepts LLC decreased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 44.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,207 shares of the company’s stock after selling 43,724 shares during the period. Exchange Traded Concepts LLC’s holdings in Compass Therapeutics were worth $103,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new stake in shares of Compass Therapeutics during the fourth quarter worth $35,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after buying an additional 11,326 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Compass Therapeutics by 25.2% during the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock valued at $404,000 after purchasing an additional 56,000 shares in the last quarter. ProShare Advisors LLC raised its position in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after acquiring an additional 9,451 shares during the period. Finally, Barclays PLC raised its position in Compass Therapeutics by 13.2% in the fourth quarter. Barclays PLC now owns 192,766 shares of the company’s stock worth $279,000 after acquiring an additional 22,521 shares during the period. Institutional investors own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

CMPX has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday, April 21st. Leerink Partnrs upgraded shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. D. Boral Capital restated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 28th. Finally, Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $13.13.

Compass Therapeutics Stock Up 3.1%

CMPX stock opened at $2.62 on Wednesday. Compass Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $4.08. The stock has a market capitalization of $362.29 million, a price-to-earnings ratio of -6.39 and a beta of 1.41. The firm’s fifty day simple moving average is $2.10 and its two-hundred day simple moving average is $2.23.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling at Compass Therapeutics

In related news, insider Jonathan Anderman acquired 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. This trade represents a 2,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 29.80% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.